Making a case for domperidone in the treatment of gastrointestinal motility disorders

Naveed Ahmad, Jeanne Keith-Ferris, Elizabeth Gooden, Thomas Abell

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

There are very few treatment options currently available for patients with gastrointestinal motility disorders, especially patients with gastroparesis. Domperidone, a peripheral dopamine receptor antagonist, has been successfully used for decades in the US and marketed in many countries for the treatment of gastroparesis. Its use, however, has recently become controversial owing to safety concerns, and it has never been approved for marketing by the FDA. During the 1990s, domperidone was available to US gastroenterologists under a compassionate-use program by Janssen Pharmaceutica, as the manufacturer worked towards, and fell short of, full US market approval. Medical studies, trials and case reports demonstrate the superior efficacy of domperidone when compared with placebo and other pharmaceutical therapies available. Data on the cardiac toxicity associated with oral use of domperidone fail to be convincing.

Original languageEnglish (US)
Pages (from-to)571-576
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume6
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

Domperidone
Gastrointestinal Motility
Gastroparesis
Compassionate Use Trials
Dopamine Antagonists
Therapeutics
Marketing
Placebos
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Making a case for domperidone in the treatment of gastrointestinal motility disorders. / Ahmad, Naveed; Keith-Ferris, Jeanne; Gooden, Elizabeth; Abell, Thomas.

In: Current Opinion in Pharmacology, Vol. 6, No. 6, 12.2006, p. 571-576.

Research output: Contribution to journalArticle

Ahmad, Naveed ; Keith-Ferris, Jeanne ; Gooden, Elizabeth ; Abell, Thomas. / Making a case for domperidone in the treatment of gastrointestinal motility disorders. In: Current Opinion in Pharmacology. 2006 ; Vol. 6, No. 6. pp. 571-576.
@article{1d01a8d6815e4cfe974f81eaf08bfe61,
title = "Making a case for domperidone in the treatment of gastrointestinal motility disorders",
abstract = "There are very few treatment options currently available for patients with gastrointestinal motility disorders, especially patients with gastroparesis. Domperidone, a peripheral dopamine receptor antagonist, has been successfully used for decades in the US and marketed in many countries for the treatment of gastroparesis. Its use, however, has recently become controversial owing to safety concerns, and it has never been approved for marketing by the FDA. During the 1990s, domperidone was available to US gastroenterologists under a compassionate-use program by Janssen Pharmaceutica, as the manufacturer worked towards, and fell short of, full US market approval. Medical studies, trials and case reports demonstrate the superior efficacy of domperidone when compared with placebo and other pharmaceutical therapies available. Data on the cardiac toxicity associated with oral use of domperidone fail to be convincing.",
author = "Naveed Ahmad and Jeanne Keith-Ferris and Elizabeth Gooden and Thomas Abell",
year = "2006",
month = "12",
doi = "10.1016/j.coph.2006.07.004",
language = "English (US)",
volume = "6",
pages = "571--576",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Making a case for domperidone in the treatment of gastrointestinal motility disorders

AU - Ahmad, Naveed

AU - Keith-Ferris, Jeanne

AU - Gooden, Elizabeth

AU - Abell, Thomas

PY - 2006/12

Y1 - 2006/12

N2 - There are very few treatment options currently available for patients with gastrointestinal motility disorders, especially patients with gastroparesis. Domperidone, a peripheral dopamine receptor antagonist, has been successfully used for decades in the US and marketed in many countries for the treatment of gastroparesis. Its use, however, has recently become controversial owing to safety concerns, and it has never been approved for marketing by the FDA. During the 1990s, domperidone was available to US gastroenterologists under a compassionate-use program by Janssen Pharmaceutica, as the manufacturer worked towards, and fell short of, full US market approval. Medical studies, trials and case reports demonstrate the superior efficacy of domperidone when compared with placebo and other pharmaceutical therapies available. Data on the cardiac toxicity associated with oral use of domperidone fail to be convincing.

AB - There are very few treatment options currently available for patients with gastrointestinal motility disorders, especially patients with gastroparesis. Domperidone, a peripheral dopamine receptor antagonist, has been successfully used for decades in the US and marketed in many countries for the treatment of gastroparesis. Its use, however, has recently become controversial owing to safety concerns, and it has never been approved for marketing by the FDA. During the 1990s, domperidone was available to US gastroenterologists under a compassionate-use program by Janssen Pharmaceutica, as the manufacturer worked towards, and fell short of, full US market approval. Medical studies, trials and case reports demonstrate the superior efficacy of domperidone when compared with placebo and other pharmaceutical therapies available. Data on the cardiac toxicity associated with oral use of domperidone fail to be convincing.

UR - http://www.scopus.com/inward/record.url?scp=33750511570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750511570&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2006.07.004

DO - 10.1016/j.coph.2006.07.004

M3 - Article

C2 - 16997628

AN - SCOPUS:33750511570

VL - 6

SP - 571

EP - 576

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 6

ER -